Dose delivery characteristics and lung deposition of indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF) and IND/MF via Breezhaler(R) device: An Alberta Idealised Throat (AIT) evaluation
Conclusion: Both IND/GLY/MF and IND/MF FDC products demonstrated similar lung deposition and highly consistent doses over the wide range of investigated flow rates, despite differences in the composition of the formulations. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Jauernig, J., Fiebich, K., Singh, D., Jaumont, X., Mezzi, K., Jaumont, X. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
"Smart" inhalers: is there a role in the management of severe asthma?
We report the utility of using "smart" inhaler technology to objectively address inhaled therapy in severe asthma patients who meet criteria for biologics.Methods: Consecutive consenting patients meeting criteria for biologics had their existing high-dose ICS/LABA//LAMA combination inhaler/s switched to mometasone/indacaterol/glycopyrronium (Enerzair® Breezhaler®). This inhaler comes with a sensor that connects via Bluetooth to an app, which records every inhaler use. Inhaler technique and the use of the app were taught, exhaled nitric oxide levels (FeNO) checked and ACQ-6 recorded at baseline. At 4 weeks adherence...
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: See, Y. Y., Chow, E. C. Y., Crooks, M., Robinson, M., Watkins, K., Turner, F., Thompson, J., Faruqi, S. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
Utility of "smart" inhaler and suppression of fractional exhaled nitric oxide (FeNO): does it make a difference to patient outcomes?
Conclusion: Utilisation of smart inhalers together with FeNO suppression is feasible objective measure. FeNO suppression in conjunction with good adherence and improved asthma control suggests that objective monitoring may lead to better asthma control. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: See, Y. Y., Chow, E. C. Y., Crooks, M., Robinson, M., Watkins, K., Turner, F., Thompson, J., Faruqi, S., Chow, E. C. Y. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
Effect of momethasone furoate combined with loratadine and montelukast sodium on inflammatory factors and pulmonary function in children with allergic rhinitis
CONCLUSION: Both mometasone furoate combined with either loratadine or montelukast sodium had good effects in AR, while the first option had a faster inhibitory effect on inflammatory factors and a better protection of lung function in children.PMID:36398245 | PMC:PMC9641454 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - November 18, 2022 Category: Research Authors: Weili Dai Ni Zhen Xiaoyan Qin Jingpeng Cao Source Type: research
Does Clearance of Vulvar Lichen Sclerosus after a Corticosteroid Treatment Correspond to a Decrease in Disease-Related Burden? Results from a Cohort Study Using Pictorial Representation of Illness and Self-Measure and the Dermatology Life Quality Index
Conclusions: VLS clearance corresponded to a significant improvement in the QoL of VLS patients, also in comparison with those who achieved a substantial but incomplete decrease of symptom and sign scores, and should become an ideal therapeutic goal.Dermatology (Source: Dermatology)
Source: Dermatology - November 16, 2022 Category: Dermatology Source Type: research
Using SMART Regimens in PHM
PHM Session: Get SMART: Implementation of updated asthma guidelines for pediatric hospitalists
Presenters: Alexander Hogan, MD, MS, Connecticut Children’s Medical Center, Hartford, Conn., Kathryn Kyler, MD, MSc, and Claire Seguin, MD, Children’s Mercy Kansas City, Mo.
This session focused on how pediatric hospitalists can improve the asthma care of patients discharged from hospitalizations by instituting single maintenance and reliever therapy (SMART) regimens. More specifically, this is a single inhaler that includes both an inhaled corticosteroid (ICS) and a long-acting beta-agonist (LABA), which have U.S. Food and D...
Source: The Hospitalist - September 23, 2022 Category: Hospital Management Authors: Lisa Casinger Tags: Adolescent Medicine Asthma Clinical Guidelines Pediatrics Source Type: research
